Myocardial protection by selective poly(ADP-ribose) polymerase inhibitors

Experimental and Clinical Cardiology

Volumn 9, Issue 1, 2004, Pages 17-20

  Kovacs, Krisztina ^a   Toth, Ambrus ^a,b   Deres, Peter ^a   Kalai, Tamas ^a   Hideg, Kalman ^a   Sumegi, Balazs ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b BOSTON BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

Akt; Energy metabolism; Heart; Ischemia reperfusion; Poly(ADP ribose) polymerase

Indexed keywords

ADENOSINE TRIPHOSPHATE; DNA; LIPID; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SINGLE STRANDED DNA; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL COMPOSITION; CELL METABOLISM; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG SELECTIVITY; ENERGY METABOLISM; ENZYME ACTIVATION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; INHIBITION KINETICS; ISOLATED HEART; LIPID PEROXIDATION; MALE; MITOCHONDRIAL RESPIRATION; MYOCARDIAL DISEASE; NONHUMAN; OXIDATION; OXIDATIVE STRESS; RAT; RESPIRATORY CHAIN; SIGNAL TRANSDUCTION; VASODILATATION;

EID: 2942676621     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Cuzzocrea S, Riley DP, Caputi AP, Salvemini D. Antioxidant therapy: A new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev 2001;53:135-59.
2. Gilad E, Zingarelli B, Salzman AL, Szabo C. Protection by inhibition of poly (ADP-ribose) synthetase against oxidant injury in cardiac myoblasts in vitro. J Mol Cell Cardiol 1997;29:2585-97.
3. Ha HC, Snyder SH. Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci USA 1999;96:13978-82.
4. Pieper AA, Walles T, Wei G, et al. Myocardial postischemic injury is reduced by polyADPripose polymerase-1 gene disruption. Mol Med 200;6:271-82.
5. Thiemermann C, Bowes J, Myint FP, Vane JR. Inhibition of the activity of poly(ADP-ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proc Natl Acad Sci USA 1997;94:679-83.
6. Halmosi R, Berente Z, Osz E, Toth K, Literati-Nagy P, Sumegi B. Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion-induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system. Mol Pharmacol 2001;59:1497-505.
7. Buja LM, Eigenbrodt ML, Eigenbrodt EH. Apoptosis and necrosis. Basic types and mechanisms of cell death. Arch Pathol Lab Med 1993;117:1208-14.
8. Saraste A, Pulkki K, Kallajoki M, Henriksen K, Parvinen M, Voipio-Pulkki LM. Apoptosis in human acute myocardial infarction. Circulation 1997;95:320-3.
9. Mockridge JW, Marber MS, Heads RJ. Activation of Akt during simulated ischemia/reperfusion in cardiac myocytes. Biochem Biophys Res Commun 2000;270:947-52.
10. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997;278:687-9.
11. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999;401:86-90.
12. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999;399:601-5.
13. National Institutes of Health. Guide for the Care and Use of Laboratory Animals. NIH Publication No 85-23. Bethesda: National Institutes of Health, 1985 (revised 1996).
14. Szabados E, Literati-Nagy P, Farkas B, Sumegi B. BGP-15, a nicotinic amidoxime derivate protecting heart from ischemia reperfusion injury through modulation of poly(ADP-ribose) polymerase. Biochem Pharmacol 2000;59:937-45.
15. Fishbein MC, Meerbaum S, Rit J, et at. Early phase acute myocardial infarct size quantification: Validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J 1981;101:593-600.
16. Chopra K, Singh M, Kaul N, Andrabi KI, Ganguly NK. Decrease of myocardial infarct size with desferrioxamine: Possible role of oxygen free radicals in its ameliorative effect. Mol Cell Biochem 1992;113:71-6.
17. Oliver CN, Ahn BW, Moerman EJ, Goldstein S, Stadtman ER. Age-related changes in oxidized proteins. J Biol Chem 1987;262:5488-91.
18. Arsham AM, Howell JJ, Simon MC. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 2003;278:29655-60.
19. Takano T, Sada K, Yamamura H. Role of protein-tyrosine kinase syk in oxidative stress signaling in B cells. Antioxid Redox Signal 2002;4:533-41.
20. Takano H, Zou Y, Hasegawa H, Akazawa H, Nagai T, Komuro I. Oxidative stress-induced signal transduction pathways in cardiac myocytes: Involvement of ROS in heart diseases. Antioxid Redox Signal 2003;5:789-94.
21. Steenbergen C. The role of p38 mitogen-activated protein kinase in myocardial ischemia/reperfusion injury; relationship to ischemic preconditioning. Basic Res Cardiol 2002;97:276-85.